Pasar al contenido principal

DIAGNOSTICO ETIOLOGICO DE LOS TRASTORNOS DE CONDUCCION AVANZADOS

PI17/01941

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL HOSPITAL UNIV. PUERTA DE HIERRO MAJADAHONDA (IDIPHIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction

  • Amor-Salamanca, Almudena|||0000-0003-0420-8207
  • Santana Rodríguez, Alfredo
  • Rasoul, Hazhee|||0000-0002-4918-5304
  • Rodríguez-Palomares, José F.
  • Moldovan, Oana
  • Hey, Thomas Morris|||0000-0003-0262-7774
  • Gallego-Delgado, María|||0000-0003-0726-9646
  • Cuenca, David López|||0000-0003-3031-8768
  • de Castro Campos, Daniel|||0000-0003-1975-9132
  • Basurte-Elorz, María Teresa|||0000-0002-8689-0301
  • Macías-Ruiz, Rosa|||0000-0003-4686-5678
  • Fuentes Cañamero, María Eugenia|||0000-0003-1239-1275
  • Galvin, Joseph|||0000-0002-3617-8738
  • Bilbao Quesada, Raquel|||0000-0002-0505-9082
  • de la Higuera Romero, Luis
  • Trujillo-Quintero, Juan Pablo|||0000-0001-5901-9388
  • García-Cruz, Loida María
  • Cárdenas-Reyes, Ivonne
  • Jiménez-Jáimez, Juan|||0000-0001-5541-898X
  • García-Hernández, Soledad|||0000-0003-2547-685X
  • Valverde-Gómez, María|||0000-0002-4371-3620
  • Gómez-Díaz, Iria
  • Limeres Freire, Javier|||0000-0003-3644-9494
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Gimeno-Blanes, Juan R.|||0000-0001-5818-1754
  • Savattis, Konstantinos
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Ochoa, Juan Pablo|||0000-0002-7966-0313
Less than 40% of patients with dilated cardiomyopathy (DCM) have a pathogenic/likely pathogenic genetic variant identified. TBX20 has been linked to congenital heart defects; although an association with left ventricular noncompaction (LVNC) and DCM has been proposed, it is still considered a gene with limited evidence for these phenotypes. This study sought to investigate the association between the TBX20 truncating variant (TBX20tv) and DCM/LVNC. TBX20 was sequenced by next-generation sequencing in 7463 unrelated probands with a diagnosis of DCM or LVNC, 22 773 probands of an internal comparison group (hypertrophic cardiomyopathy, channelopathies, or aortic diseases), and 124 098 external controls (individuals from the gnomAD database). Enrichment of TBX20tv in DCM/LVNC was calculated, cosegregation was determined in selected families, and clinical characteristics and outcomes were analyzed in carriers. TBX20tv was enriched in DCM/LVNC (24/7463; 0.32%) compared with internal (1/22 773; 0.004%) and external comparison groups (4/124 098; 0.003%), with odds ratios of 73.23 (95% CI, 9.90-541.45; P <0.0001) and 99.76 (95% CI, 34.60-287.62; P <0.0001), respectively. TBX20tv was cosegregated with DCM/LVNC phenotype in 21 families for a combined logarythm of the odds score of 4.53 (strong linkage). Among 57 individuals with TBX20tv (49.1% men; mean age, 35.9±20.8 years), 41 (71.9%) exhibited DCM/LVNC, of whom 14 (34.1%) had also congenital heart defects. After a median follow-up of 6.9 (95% CI, 25-75:3.6-14.5) years, 9.7% of patients with DCM/LVNC had end-stage heart failure events and 4.8% experienced malignant ventricular arrhythmias. TBX20tv is associated with DCM/LVNC; congenital heart defect is also present in around one-third of cases. TBX20tv -associated DCM/LVNC is characterized by a nonaggressive phenotype, with a low incidence of major cardiovascular events. TBX20 should be considered a definitive gene for DCM and LVNC and routinely included in genetic testing panels for these phenotypes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical Risk Score to Predict Pathogenic Genotypes in Patients With Dilated Cardiomyopathy

  • Escobar-Lopez, Luis|||0000-0002-4354-7263
  • Ochoa, Juan Pablo|||0000-0002-7966-0313
  • Royuela, Ana
  • Verdonschot, Job A.J.
  • Ferro, Matteo Dal
  • Espinosa, Maria Angeles
  • Sabater-Molina, Maria
  • Gallego-Delgado, María|||0000-0003-0726-9646
  • Larrañaga-Moreira, Jose M.
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Basurte-Elorz, María Teresa|||0000-0002-8689-0301
  • Rodríguez Palomares, José F.|||0000-0002-7229-9780
  • Climent, Vicente|||0000-0001-7362-1922
  • Bermudez Jimenez, Francisco J.|||0000-0003-0325-7349
  • Mogollón-Jiménez, María Victoria
  • Lopez, Javier
  • Peña-Peña, Maria Luisa
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • López-Abel, Bernardo
  • Ripoll-Vera, Tomás|||0000-0001-9222-325X
  • Palomino-Doza, Julian
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Brugada, Ramon|||0000-0001-6607-3032
  • Idiazabal, Uxua
  • Mirelis, Jesus G.
  • Dominguez, Fernando
  • Henkens, Michiel T.H.M.
  • Krapels, Ingrid P.C.
  • Brunner, Han G.
  • Paldino, Alessia
  • Zaffalon, Denise
  • Mestroni, Luisa
  • Sinagra, Gianfranco|||0000-0003-2700-8478
  • Heymans, Stephane R.B.
  • Merlo, Marco|||0000-0002-1022-3131
  • García-Pavia, Pablo
Although genotyping allows family screening and influences risk-stratification in patients with nonischemic dilated cardiomyopathy (DCM) or isolated left ventricular systolic dysfunction (LVSD), its result is negative in a significant number of patients, limiting its widespread adoption. This study sought to develop and externally validate a score that predicts the probability for a positive genetic test result (G+) in DCM/LVSD. Clinical, electrocardiogram, and echocardiographic variables were collected in 1,015 genotyped patients from Spain with DCM/LVSD. Multivariable logistic regression analysis was used to identify variables independently predicting G+, which were summed to create the Madrid Genotype Score. The external validation sample comprised 1,097 genotyped patients from the Maastricht and Trieste registries. A G+ result was found in 377 (37%) and 289 (26%) patients from the derivation and validation cohorts, respectively. Independent predictors of a G+ result in the derivation cohort were: family history of DCM (OR: 2.29; 95% CI: 1.73-3.04; P < 0.001), low electrocardiogram voltage in peripheral leads (OR: 3.61; 95% CI: 2.38-5.49; P < 0.001), skeletal myopathy (OR: 3.42; 95% CI: 1.60-7.31; P = 0.001), absence of hypertension (OR: 2.28; 95% CI: 1.67-3.13; P < 0.001), and absence of left bundle branch block (OR: 3.58; 95% CI: 2.57-5.01; P < 0.001). A score containing these factors predicted a G+ result, ranging from 3% when all predictors were absent to 79% when ≥4 predictors were present. Internal validation provided a C-statistic of 0.74 (95% CI: 0.71-0.77) and a calibration slope of 0.94 (95% CI: 0.80-1.10). The C-statistic in the external validation cohort was 0.74 (95% CI: 0.71-0.78). The Madrid Genotype Score is an accurate tool to predict a G+ result in DCM/LVSD. (J Am Coll Cardiol 2022;80:1115-1126) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis, a new endemic variant in Spain

  • De Frutos, Fernando|||0000-0003-4350-3217
  • Ochoa, Juan Pablo|||0000-0002-7966-0313
  • Gómez-González, Cristina
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Aróstegui, Juan Ignacio|||0000-0003-4757-504X
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Barriales-Villa, Roberto|||0000-0002-6721-3487
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Gonzalez-Lopez, Esther
  • Ramil, Elvira
  • Galan, Lucia
  • González-Costello, José|||0000-0002-7437-3630
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Espinosa, Maria Angeles
  • García-Pavía, Pablo|||0000-0002-5470-2257
The p.Glu109Lys variant (Glu89Lys) is a rare cause of hereditary transthyretin amyloidosis (ATTRv) for which clinical spectrum remains unresolved. We sought to describe the clinical characteristics and outcomes of ATTR Glu89Lys amyloidosis and assess a potential founder effect in Spain. Patients with the p.Glu109Lys ATTRv variant from 14 families were recruited at 7 centres. Demographics, complementary tests and clinical course were analysed. Haplotype analysis was performed in 7 unrelated individuals. Thirty-eight individuals (13 probands, mean age 40.4 ± 13.1 years) were studied. After median follow-up of 5.1 years (IQR 1.7-9.6), 7 patients died and 7 required heart transplantation (median age at transplantation 50.5 years). Onset of cardiac and neurological manifestations occurred at a mean age of 48.4 and 46.8 years, respectively. Median survival from birth was 61.6 years and no individual survived beyond 65 years. Patients treated with disease-modifying therapies exhibited better prognosis (p < 0.001). Haplotype analysis revealed a common origin from an ancestor who lived ∼500 years ago in southeast Spain. Glu89Lys ATTRv is a TTR variant with a founder effect in Spain. It is associated with near complete penetrance, early onset and mixed cardiac and neurologic phenotype. Patients have poor prognosis, particularly if not treated with disease-modifying therapies.